Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
Abel EV; Basile KJ; Kugel CH 3rd; Witkiewicz AK; Le K; Amaravadi RK; Karakousis GC; Xu X; Xu W; Schuchter LM; Lee JB; Ertel A; Fortina P; Aplin AE; The Journal Of Clinical Investigation, 2013, vol. 123, issue 5, p 2155, ISSN 15588238. ISBN 15588238.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef